Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers

Breast Cancer Research and Treatment

Volumn 133, Issue 1, 2012, Pages 311-320

  Park, Seho ^a,b   Park, Hyung Seok ^a   Koo, Ja Seung ^a,b   Yang, Woo Ick ^a   Kim, Seung Il ^a,b   Park, Byeong Woo ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Target Molecule Study Group   (South Korea)

Author keywords

Androgen receptor; Breast cancer; Estrogen receptor; Predictive factor; Prognosis

Indexed keywords

ANDROGEN RECEPTOR; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAXANE DERIVATIVE;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER SIZE; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROLIFERATION INDEX; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENTINEL LYMPH NODE BIOPSY; TISSUE MICROARRAY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, HORMONE-DEPENDENT; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84860334873     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1950-z     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
2. PL Bedard OC Freedman A Howell, et al. 2008 Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? Breast Cancer Res Treat 108 307 317 10.1007/s10549-007-9606-8 18351454 10.1007/s10549-007-9606-8 1:CAS:528:DC%2BD1cXjsFGisb4%3D (Pubitemid 351431070)
3. CX Ma CG Sanchez MJ Ellis 2009 Predicting endocrine therapy responsiveness in breast cancer Oncology (Williston Park) 23 133 142
4. JM Harvey GM Clark CK Osborne, et al. 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474 1481 10334533 1:STN:280:DyaK1M3msFOjsA%3D%3D (Pubitemid 29220854)
5. X Cui R Schiff G Arpino, et al. 2005 Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J Clin Oncol 23 7721 7735 10.1200/JCO.2005.09.004 16234531 10.1200/JCO.2005.09.004 1:CAS:528:DC%2BD2MXht1WrsrrM (Pubitemid 46291836)
6. S Paik S Shak G Tang, et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817 2826 10.1056/NEJMoa041588 15591335 10.1056/NEJMoa041588 1:CAS:528: DC%2BD2MXhslymsw%3D%3D (Pubitemid 40051905)
7. MJ van de Vijver YD He LJ van't Veer, et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 1999 2009 10.1056/NEJMoa021967 12490681 10.1056/NEJMoa021967 (Pubitemid 35461656)
8. DA Berry C Cirrincione IC Henderson, et al. 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658 1667 10.1001/jama.295.14.1658 16609087 10.1001/jama.295.14. 1658 1:CAS:528:DC%2BD28XjsVeqs7k%3D
9. F Montemurro M Aglietta 2009 Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy Endocr Relat Cancer 16 1091 1102 10.1677/ERC-09-0033 19726539 10.1677/ERC-09-0033
10. M Colleoni V Bagnardi N Rotmensz, et al. 2009 Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy Breast Cancer Res Treat 116 359 369 10.1007/s10549-008-0223-y 18941889 10.1007/s10549-008-0223-y 1:CAS:528:DC%2BD1MXntF2ntrY%3D
11. RW Carlson DC Allred BO Anderson, et al. 2009 Breast cancer. Clinical practice guidelines in oncology J Natl Compr Cancer Netw 7 122 192 1:CAS:528:DC%2BD1MXjs1Oktbg%3D
12. A Goldhirsch JN Ingle RD Gelber, et al. 2009 Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 1319 1329 10.1093/annonc/mdp322 19535820 10.1093/annonc/mdp322 1:STN:280:DC%2BD1Mrjtlyhug%3D%3D
13. S Park JS Koo MS Kim, et al. 2011 Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers Ann Oncol 22 1755 1762 10.1093/annonc/mdq678 21310761 10.1093/annonc/mdq678 1:STN:280:DC%2BC3MjhsFOitQ%3D%3D
14. I Castellano E Allia V Accortanzo, et al. 2010 Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers Breast Cancer Res Treat 124 607 617 10.1007/s10549-010-0761-y 20127405 10.1007/s10549-010-0761-y 1:CAS:528:DC%2BC3cXhtlyrsrvF
15. SN Agoff PE Swanson H Linden, et al. 2003 Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations Am J Clin Pathol 120 725 731 10.1309/42F0-0D0D-JD0J-5EDT 14608899 10.1309/42F00D0DJD0J5EDT 1:CAS:528:DC%2BD3sXpsVOnsL8%3D (Pubitemid 37339680)
16. R Hu S Dawood MD Holmes, et al. 2011 Androgen receptor expression and breast cancer survival in postmenopausal women Clin Cancer Res 17 1867 1874 10.1158/1078-0432.CCR-10-2021 21325075 10.1158/1078-0432.CCR-10-2021 1:CAS:528:DC%2BC3MXktVOisL0%3D
17. S Park J Koo HS Park, et al. 2010 Expression of androgen receptors in primary breast cancer Ann Oncol 21 488 492 10.1093/annonc/mdp510 19887463 10.1093/annonc/mdp510 1:STN:280:DC%2BC3c7isV2hsg%3D%3D
18. JN Ingle DI Twito DJ Schaid, et al. 1991 Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis Cancer 67 886 891 1991261 10.1002/1097-0142(19910215)67:4<886::AID-CNCR2820670405>3.0.CO;2-O 1:STN:280:DyaK3M7itFekug%3D%3D
19. LF Macedo Z Guo SL Tilghman, et al. 2006 Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole Cancer Res 66 7775 7782 10.1158/0008-5472.CAN-05-3984 16885381 10.1158/0008-5472.CAN-05- 3984 1:CAS:528:DC%2BD28XnsFyqsrc%3D (Pubitemid 44289238)
20. F De Amicis J Thirugnansampanthan Y Cui, et al. 2010 Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells Breast Cancer Res Treat 121 1 11 10.1007/s10549-009-0436-8 19533338 10.1007/s10549-009-0436-8 1:CAS:528:DC%2BC3cXkvVymtL0%3D
21. E von Elm DG Altman M Egger, et al. 2007 The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies Lancet 370 1453 1457 10.1016/S0140-6736(07) 61602-X 10.1016/S0140-6736(07)61602-X
22. Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York
23. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 1757079 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D
24. ME Hammond DF Hayes M Dowsett, et al. 2010 American society of clinical oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2784 2795 10.1200/JCO.2009.25.6529 20404251 10.1200/JCO.2009.25.6529
25. AC Wolff ME Hammond JN Schwartz, et al. 2007 American society of clinical oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 10.1200/JCO.2006.09.2775 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
26. F Rastelli S Crispino 2008 Factors predictive of response to hormone therapy in breast cancer Tumori 94 370 383 18705406
27. SJ Cleator E Ahamed RC Coombes, et al. 2009 A 2009 update on the treatment of patients with hormone receptor-positive breast cancer Clin Breast Cancer 9 S6 S17 10.3816/CBC.2009.s.001 19561006 10.3816/CBC.2009.s.001 1:CAS:528:DC%2BD1MXpt1Ontrg%3D
28. RE Moe BO Anderson 2007 Androgens and androgen receptors: a clinically neglected sector in breast cancer biology J Surg Oncol 95 437 439 10.1002/jso.20722 17192921 10.1002/jso.20722 (Pubitemid 46709384)
29. Q Yu Y Niu N Liu, et al. 2011 Expression of androgen receptor in breast cancer and its significance as a prognostic factor Ann Oncol 22 1288 1294 10.1093/annonc/mdq586 21109569 10.1093/annonc/mdq586 1:STN:280: DC%2BC3MrkvFOntA%3D%3D
30. S Loibl BM Muller G von Minckwitz, et al. 2011 Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy Breast Cancer Res Treat 130 477 487 10.1007/s10549-011-1715-8 21837479 10.1007/s10549-011-1715-8 1:CAS:528:DC%2BC3MXht1yktLrM
31. PM Ravdin LA Siminoff GJ Davis, et al. 2001 Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer J Clin Oncol 19 980 991 11181660 1:STN:280:DC%2BD3M3gsFalsg%3D%3D (Pubitemid 32176272)
32. LL Chen ME Nolan MJ Silverstein, et al. 2009 The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death Cancer 115 5071 5083 10.1002/cncr.24565 19658184 10.1002/cncr.24565
33. JS Koo W Jung J Jeong 2009 The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer Jpn J Clin Oncol 39 560 568 10.1093/jjco/hyp065 19531543 10.1093/jjco/hyp065